Bank interest income was $11m on average cash of around $210m, around 5.23% interest rate. NEU currently has around $353m cash on hand (As all milestone payments (US$50m x 2 already received; less, monthly cash outflow for R&D and corporate & admin costs ~$3.2m/month).
Royalties from DAYBUE for 2025 will be around $62m - $67m based on AUD at 65c.
Interest income on average balance of $300m is very conservative, would earn interest income of around $15m for 2025, imo. That would bring total income for 2025 to ~$80m.
Regarding the milestone payments, some are easy to meet, like first sales in Europe, US$35m, first sales in Japan, US$15m. That's total of US$50m, probably within next three years.
Sales milestone payments, are slightly different, it appears 14.3% of the total sales milestone payments are easily achievable, like US$250m in U.S., then next 14.3% are relatively hard to met (i.e. US$500m in U.S.). The total milestone payments for ex-North America are US$363m, 14.3% of that, is US$51.9m. It's very likely that first US$51.9m milestone payments are relatively easy to be earned.
I read some estimated US peak sales for DAYBUE would be between US$600m and US$800m. If that occurred, another US$50m would come. For next milestone of US$100m for annual sales of US$750m is very hard, imo.
To sum up, around US$101.9m milestone payments on the sales, are relative easy to be earned in the future; if goes very well, then could earn additional milestone payments up to US$611m, from DAYBUE, and these payments are pure profit as Acadia bears all the costs.
SKYCLARYS Europe sales are around 43% of the US sales last quarter, not sure if that would be the case for DAYBUE. Let's work on that percentage for now, if US sales are US$400m, then Europe sales would be around US$172m, then total annual royalties would be around US$73m (or $112m, AUD/USD:65c). So I believe our annual royalties from DAYBUE should exceed $100m once successful launching Europe sales.
All IMO. Not advice.
![]()
- Forums
- ASX - By Stock
- NEU
- Ann: 2024 Full Year Results webinar
NEU
neuren pharmaceuticals limited
Add to My Watchlist
1.07%
!
$12.96

Ann: 2024 Full Year Results webinar, page-71
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$12.96 |
Change
-0.140(1.07%) |
Mkt cap ! $1.612B |
Open | High | Low | Value | Volume |
$13.20 | $13.36 | $12.82 | $4.627M | 354.8K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 7585 | $12.96 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$13.03 | 3344 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 7585 | 12.960 |
1 | 588 | 12.950 |
2 | 1799 | 12.910 |
2 | 3925 | 12.900 |
3 | 2813 | 12.890 |
Price($) | Vol. | No. |
---|---|---|
13.030 | 3344 | 2 |
13.050 | 1296 | 2 |
13.060 | 1291 | 1 |
13.070 | 2890 | 3 |
13.080 | 3090 | 3 |
Last trade - 16.10pm 16/06/2025 (20 minute delay) ? |
Featured News
NEU (ASX) Chart |